Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gileadâs Veklury, Amgenâs Kyprolis, Baxterâs Nexterone, and Acrotech Biopharmaâs Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
髿é·
å瀟ã®åçã¯éå»3幎éã«ãããçå®ã«å¢å ããŠããã幎平åã§104.16%ã®æé·çã瀺ããŠããŸãã
é«ãå©çæé·
å瀟ã®çŽå©çã¯æ¥çããªãŒãããŠãããææ°ã®å¹ŽéçŽå©çã¯USD 268.09Mã§ãã
é»å転æ
å瀟ã¯é»å転æãæãããææ°ã®å¹ŽéçŽå©çã¯USD ã§ãã
驿£æ°Žæº
åç€Ÿã®ææ°ã®PEã¯37.13ã§ãéå»3幎éã®æ°Žæºãšæ¯èŒããŠé©æ£åã«ãããŸãã
æ©é¢æè³å®¶ã®å£²ãè¶ã
ææ°ã®æ©é¢æè³å®¶ã®ä¿ææ ªæ°ã¯20.97Mæ ªã§ãåååææ¯ã§2.30%æžå°ããŠããŸãã
ãã©ã€ããŒãã»ãã£ãã¿ã«ãä¿æ
ã¹ã¿ãŒæè³å®¶ãã©ã€ããŒãã»ãã£ãã¿ã«ã¯æ¬éæã170.46Kæ ªä¿æããŠããŸãã
åžå ޿޻åãæŽ»çº
å瀟ãžã®æè³å®¶ã®é¢å¿ãé«ãŸã£ãŠããã20æ¥éã®å£²è²·å転çã¯1.03ã§ãã